Evidence map›Paper›PMID 39880607›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2025

Hans's algorithm and MYD88

Yuka Oka, Shoki Yamada, Moe Takeda, Yuko Hashimoto

Abstract read
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuka OkaDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shoki YamadaDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Moe TakedaDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yuko HashimotoDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary central nervous system (CNS) lymphomas account for 1.9-3% of all brain tumors, with the majority being histologically classified as primary large B-cell lymphoma of the CNS (PCNS-LBCL). PCNS-LBCL is characterized by mature germinal center-exit B cells, and most cases of this phenotype are classified as activated B-cell-like phenotype according to gene expression profiling, or as non-germinal center B-cell-like phenotype (non-GCB type) according to Hans's algorithm. Genetically, PCNS-LBCL often shows mutations in MYD88

Indexed as

AlgorithmsCentral Nervous System NeoplasmsLymphoma, B-CellMutationMyeloid Differentiation Factor 88AdultAgedAged, 80 and overCD79 AntigensFemaleHumansMaleMiddle AgedPrognosisCD79 AntigensMYD88 protein, humanMyeloid Differentiation Factor 88CD79BY196 mutationHans’s algorithmMYD88L265P mutationprimary large B-cell lymphoma of the CNSSanger sequencing

Identifiers

PMID39880607
PMCPMC12051415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.